← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Thermo Fisher Scientific TMO $256B	2,386	+11	+0.5%	$196B
2	2 Danaher DHR $162B	2,078	-42	-2%	$144B
3	3 Regeneron Pharmaceuticals REGN $82.9B	1,191	+33	+3%	$76.1B
4	4 Novartis NVS $287B	1,180	-2	-0.2%	$15.2B
5	5 Agilent Technologies A $49.5B	983	+19	+2%	$36.2B
6	6 Illumina ILMN $40.5B	946	+3	+0.3%	$33B
7	7 Charles River Laboratories CRL $14.7B	621	-6	-1%	$10.3B
8	8 Revvity RVTY $17.4B	563	-51	-8%	$14.1B
9	9 DELISTED CATALENT, INC. CTLT	526	+41	+8%	$12.5B
10	10 Alnylam Pharmaceuticals ALNY $31.2B	477	-10	-2%	$24B
11	11 Sarepta Therapeutics SRPT $1.88B	426	+15	+4%	$11.2B
12	12 CRISPR Therapeutics CRSP $4.96B	381	-15	-4%	$2.54B
13	13 Azenta AZTA $1.6B	342	-8	-2%	$3.15B
14	14 Bruker BRKR $8.57B	318	+16	+5%	$8.16B
15	15 Ionis Pharmaceuticals IONS $7.32B	314	-25	-7%	$4.69B
16	16 Ginkgo Bioworks DNA $772M	313	-7	-2%	$1.51B
17	17 ARK Genomic Revolution ETF ARKG $2.07B	297	-24	-7%	$669M
18	18 Intellia Therapeutics NTLA $1.63B	291	-11	-4%	$2.93B
19	19 Qiagen QGEN $9.56B	287	-9	-3%	$6.24B
20	20 Guardant Health GH $22.1B	279	-11	-4%	$2.17B
21	NVTA 21 DELISTED Invitae Corporation NVTA	271	-4	-1%	$247M
22	22 Pacific Biosciences PACB $594M	259	+24	+10%	$2.93B
23	23 10x Genomics TXG $9.21B	258	-8	-3%	$5.03B
24	24 Arrowhead Research ARWR $8.25B	255	-25	-9%	$1.85B
25	25 Editas Medicine EDIT $369M	235	-14	-6%	$384M